Skip to main content
Fig. 2 | BMC Pharmacology and Toxicology

Fig. 2

From: Risk comparison of adverse reactions between gemcitabine monotherapy and gemcitabine combined with albumin-bound paclitaxel in pancreatic cancer: insights from the FDA Adverse Event Reporting System (FAERS) database

Fig. 2

Visualization of clinical characteristics associated with the two treatments. (a) Line plot of the number of adverse event reports over years (b) Worldwide distribution of case reporters in G treatment (c) Worldwide distribution of case reporters in AG treatment (d) Outcome of case reporters in G treatment (e) Outcome of case reporters in AG treatment. Abbreviation G treatment, gemcitabine monotherapy; AG treatment, gemcitabine combined with albumin-bound paclitaxel

Back to article page

BMC Pharmacology and Toxicology

ISSN: 2050-6511

Contact us